SNSS : Summary for Sunesis Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets open in 27 mins.

Sunesis Pharmaceuticals, Inc. (SNSS)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.30+0.01 (+0.23%)
At close: 4:00PM EST
People also watch
CYCCTHLDRPRXAEZSSNTA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close4.29
Open4.30
Bid4.04 x 300
Ask4.99 x 100
Day's Range4.23 - 4.45
52 Week Range2.64 - 6.30
Volume87,507
Avg. Volume51,459
Market Cap89.78M
Beta1.14
PE Ratio (TTM)-1.47
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss
    Zacksyesterday

    Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss

    Shares of Achillion Pharmaceuticals, Inc. (ACHN) lost almost 9% on Feb 24, 2017, in spite of the company reporting narrower-than-expected fourth-quarter loss a day before.

  • Emergent (EBS) Beats Earnings, Revenue Estimates in Q4
    Zacks4 days ago

    Emergent (EBS) Beats Earnings, Revenue Estimates in Q4

    Emergent BioSolutions, Inc. (EBS) reported earnings of 74 cents per share in the fourth quarter of 2016, which surpassed the Zacks Consensus Estimate of 60 cents. However, the reported figure decreased from 77 cents earned in the year-ago period.

  • Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
    Zacks5 days ago

    Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line

    Bayer AG's (BAYRY) fourth-quarter 2016 core earnings increased 10.2% year over year to ???1.19 per share (approximately $1.28). Reported earnings missed the Zacks Consensus Estimate of $1.37.